Cardiology
Evaluating Riociguat in Early Pulmonary Vascular Disease: Insights from the ESRA Phase IIa Trial
The ESRA trial demonstrates that riociguat is safe and effectively reduces pulmonary vascular resistance in early pulmonary vascular disease, though secondary benefits remain unproven in this early-stage, mostly connective tissue disease-as
